Revolution Medicines
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2015-01-01
- Employees
- 378
- Market Cap
- $7.2B
- Website
- http://www.revmed.com
- Introduction
Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
- First Posted Date
- 2019-06-18
- Last Posted Date
- 2023-06-26
- Lead Sponsor
- Revolution Medicines, Inc.
- Target Recruit Count
- 113
- Registration Number
- NCT03989115
- Locations
- 🇺🇸
Honor Health Research Institute, Scottsdale, Arizona, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
- First Posted Date
- 2018-08-17
- Last Posted Date
- 2022-09-01
- Lead Sponsor
- Revolution Medicines, Inc.
- Target Recruit Count
- 133
- Registration Number
- NCT03634982
- Locations
- 🇺🇸
UC San Francisco - Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸Sarah Cannon Research Institute - Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸Sarah Cannon Research Institute - Tennessee Oncology, PLLC, Nashville, Tennessee, United States